GNH USA represents the Pharma Distribution community in China Bilateral Conference
GNH USA was invited to attend the China Bilateral Conference in 2018 as a delegate representing the pharmaceutical distribution business from the USA. The event brought together regulators and industry representatives to discuss cross-border access to specialist medicines.
A key objective of the conference was to legitimise the flow of unlicensed and orphan drugs into China, ensuring that patients can access essential medicines that may not yet be locally registered.
This focus aligns closely with GNH USA's core capabilities. As a WHO GDP-certified distributor, GNH USA specialises in named-patient and unlicensed-drug supply, helping healthcare providers and institutions source hard-to-find and orphan medicines for patients worldwide while maintaining full regulatory and cold-chain integrity.
To discuss your named-patient or unlicensed-drug sourcing requirements, get in touch with our team.